Monthly Communication Report

Organization:	Psychedelics Canada—The Canada Psychedelic Businesses Association
Associated registration:	952635-372370-1
Communication date:	2024-04-30
Posted date:	2024-05-08

Designated Public Office Holders who participated in the communication:	Kathy Soltys, Director, Office of Clinical Trials Pharmaceutical Drug Directorate, Health Canada (HC) Jennifer Pelley, Director Office of Legislative and Regulatory Affairs, Health Canada (HC) Karen Reynolds, Director General PHARMACEUTICAL DRUGS DIRECTORATE, Health Canada (HC) Rita Beregszaszy, Director Bureau of Policy, Science, and International Programs, Health Canada (HC) Cesare Spadaccini, Manager,Operational Policy OFFICE OF CONTROLLED SUBSTANCES, Health Canada (HC)
Subject Matter of the communication:	Health,  International Trade Footnote1,  Justice and Law Enforcement,  Science and Technology
Responsible Officer who filed this communication report:	Liam Bedard
As the most senior paid officer, the person named above is responsible for certifying the communication report for the corporation or organization (Registrant). This person may or may not have participated in the reported communication. The Lobbyists Registration Regulations do not require that the names of in-house lobbyists (i.e. employees of corporations or organizations) who actually participated in the communication be disclosed.
Footnote1  Indicates new information that was added through a monthly communications return.